KOD - Kodiak stock plunges 68% as KSI-301 trial for vision disorder fails to meet main goal

Kodiak Sciences's (NASDAQ:KOD) medicine KSI-301 failed to meet the main goal of a phase 2b/3 trial in patients with neovascular (wet) age-related macular degeneration who had not received prior treatment. Wet macular degeneration is a chronic eye disorder that causes blurred vision and can lead to blindness. The trial randomized 559 participants and had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. The company said results showed that KSI-301 did not meet the primary efficacy endpoint of showing non-inferior visual acuity gains for patients dosed on extended regimens compared to aflibercept given every eight weeks. "Allowing treatment with KSI-301 no more often than every 12 weeks after the loading phase for every patient turned out to be insufficient," said Kodiak's CEO Victor Perlroth. The company added that a pre-specified secondary analysis at year 1 assessing durability showed 59% of patients in the KSI-301

For further details see:

Kodiak stock plunges 68% as KSI-301 trial for vision disorder fails to meet main goal